{"filing":{"accession_number":"0001213900-26-101967","cik":"0001075880","ticker":"KZIA","company_name":"KAZIA THERAPEUTICS LTD","form":"6-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"ea0305873-6k_kazia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026101967/ea0305873-6k_kazia.htm"},"events":[{"id":34189,"run_id":31457,"accession_number":"0001213900-26-101967","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The press release announces that Sovargen Co. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders (FCD T2 and TSC), which triggers a $2 million milestone payment to Kazia and signals potential for up to $17 million in additional milestone payments. This represents a material clinical and commercial milestone for Kazia's licensed asset paxalisib, expanding its development beyond oncology into CNS indications. While this is a significant operational and strategic development for the company's licensing partnership, it does not fit neatly into the discrete event categories (not an earnings release, M\u0026A activity, debt issuance, or other named types), making it an operational milestone best classified as operational_other.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-22","form":"6-K","submitted_at":null,"items":[{"id":37857,"accession_number":"0001213900-26-101967","item_number":"EX-99.1","item_title":"ea030587301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces that Sovargen Co. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders (FCD T2 and TSC), which triggers a $2 million milestone payment to Kazia and signals potential for up to $17 million in additional milestone payments. This represents a material clinical and commercial milestone for Kazia's licensed asset paxalisib, expanding its development beyond oncology into CNS indications. While this is a significant operational and strategic development for the company's licensing partnership, it does not fit neatly into the discrete event categories (not an earnings release, M\u0026A activity, debt issuance, or other named types), making it an operational milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:16.817144+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37857,"accession_number":"0001213900-26-101967","item_number":"EX-99.1","item_title":"ea030587301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces that Sovargen Co. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders (FCD T2 and TSC), which triggers a $2 million milestone payment to Kazia and signals potential for up to $17 million in additional milestone payments. This represents a material clinical and commercial milestone for Kazia's licensed asset paxalisib, expanding its development beyond oncology into CNS indications. While this is a significant operational and strategic development for the company's licensing partnership, it does not fit neatly into the discrete event categories (not an earnings release, M\u0026A activity, debt issuance, or other named types), making it an operational milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:02:16.817144+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-09-22"}]}